Certis Oncology has announced the launch of its Certis Oncology Intelligence® Platform, an integrated system designed to advance cancer research by combining predictive and agentic artificial intelligence with biological validation.
The platform aims to address a critical challenge in oncology drug development: translating vast amounts of biological data into reliable predictions of therapeutic response. By integrating AI-driven modeling with functional biological validation in a closed-loop system, Certis intends to provide pharmaceutical and biotechnology companies with a tool to improve confidence in their translational and clinical decision-making processes, potentially accelerating the development of more effective cancer treatments.
What We Know So Far
- Certis Oncology announced the official launch of its new platform, named Certis Oncology Intelligence®, according to a press release distributed by Business Wire.
- The platform is engineered to generate data-driven insights by combining predictive modeling, agentic AI for data exploration, and functional biological validation.
- It operates as a secure, multi-tenant, closed-loop system that integrates three distinct data layers to create a comprehensive analytical environment.
- The stated goal is to assist pharmaceutical and biotech firms in enhancing the certainty of their decisions during the translational and clinical phases of drug development.
- A core component is the Predictive Intelligence Layer, CertisAI™, which is described as a patented, generalized drug-response foundation model, as reported by outlets including the Times Argus.
What is the Certis Oncology Intelligence Platform?
The Certis Oncology Intelligence Platform is an integrated technology system designed to bridge the gap between computational prediction and real-world biological outcomes in cancer research. The platform's architecture is built on a closed-loop principle, meaning that insights from each stage feed back into the system, allowing it to learn and refine its models over time. This structure is intended to create a continuously improving cycle of prediction, exploration, and validation.
The system is composed of three interconnected layers. The first is the Predictive Intelligence Layer, powered by CertisAI™, a patented foundation model specifically trained for predicting drug responses. This layer uses machine learning to analyze complex datasets and forecast how a particular cancer might respond to a therapeutic agent. The second is the Biological Intelligence Layer, which provides deep biological context to the AI's predictions. This layer incorporates a vast knowledge base of biological information to help researchers understand the "why" behind a prediction. The third layer is Functional Intelligence, which involves laboratory-based, functional validation of the AI's predictions using patient-derived xenograft (PDX) models and other advanced assays. This final step provides empirical evidence to confirm or refine the computational insights.
Peter Ellman, President and CEO of Certis, framed the platform as a direct response to a fundamental industry problem. "One of the central challenges in oncology drug development is that we generate enormous amounts of data, but struggle to translate that into reliable predictions of therapeutic response," Ellman stated in the announcement. He further explained the platform's purpose: "Certis Oncology Intelligence was built to close that gap—linking prediction, biological context, and experimental validation into a system that continuously learns and improves over time."
The Role of Predictive and Agentic AI in Oncology
The launch of the Certis platform highlights a significant trend in biotechnology: the increasing reliance on sophisticated AI to navigate the complexities of cancer biology and drug development. The integration of both predictive and agentic AI models represents a multi-faceted approach to data analysis. Predictive AI, like the CertisAI™ foundation model, excels at identifying patterns and making forecasts from large-scale data, a crucial capability in a field where genomic and proteomic information is abundant.
The inclusion of agentic AI, however, introduces a more dynamic and interactive component. Agentic systems can perform tasks autonomously, such as exploring biological data, formulating hypotheses, and suggesting experiments to validate those hypotheses. This capability moves beyond simple pattern recognition, allowing researchers to use the AI as an active partner in the scientific discovery process. By enabling AI-powered biological data exploration, the platform aims to help scientists uncover novel mechanisms of action or identify new biomarkers for drug response more efficiently than with traditional methods.
Crucially, Certis emphasizes the connection between these AI-driven insights and tangible biological validation. In oncology, purely computational predictions can be brittle and may not always translate to clinical reality. By building a system that requires its own predictions to be tested and confirmed in a laboratory setting, Certis aims to build a more robust and trustworthy model. This "ground-truthing" process, where AI predictions are validated against results from functional assays, is designed to increase the confidence that pharmaceutical companies have when making high-stakes decisions about which drug candidates to advance into clinical trials.
What Happens Next
Following the launch announcement, the Certis Oncology Intelligence Platform's immediate focus will be on its adoption and implementation by pharmaceutical and biotechnology clients. The platform's success will be measured by its ability to demonstrably improve the efficiency and accuracy of preclinical and translational research for these partners. Key performance indicators include reducing drug candidate attrition rates and accelerating the timeline from discovery to clinical trials.
How the platform's "closed-loop" learning system performs and evolves over time is a central question. As more data from biological validation experiments are fed back into the CertisAI™ model, its predictive accuracy is expected to increase. The rate and magnitude of this improvement will be a critical factor in its long-term value proposition. Industry observers will be watching for case studies or publications that demonstrate the platform's ability to generate novel, validated insights, leading to successful therapeutic development programs.
The development of the platform reflects a broader movement toward integrating complex AI systems into the core of scientific research. Certis, a company founded in 2016 with approximately 50 employees, developed this sophisticated system, underscoring the maturation of AI tools in life sciences. The next phase will involve monitoring how this technology scales and how it is integrated into the established, often rigid, workflows of large pharmaceutical organizations. The ultimate test will be whether this combination of predictive AI, agentic exploration, and biological validation can help deliver on the promise of more personalized and effective cancer therapies.
